Starpharma deal with Dow out of the bag
Thursday, 20 January, 2005
Starpharma (ASX:SPL) was forced into a trading halt this morning after a report in Melbourne broadsheet The Age revealed that Starpharma's US subsidiary Dendritic Nanotechnologies (DNT) was about to consummate an intellectual property deal with US giant Dow Chemical company.
At time of writing, Starpharma had not yet provided the market with clarification on the deal. It reportedly involves the transfer of approximately 200 of Dow's nanotechnology patents, including patents in the dendrimer field in which Starpharma specialises. Dow was to receive an equity stake in DNT as consideration.
In November, Starpharma reported positive preliminary results from the Phase I clinical trial on its dendrimer-based vaginal microbicide Vivagel.
Link between oestrogen and heart health found in women
Scientists found that oestrogen helps increase the ANXA1 protein, and when ANXA1 is missing, the...
Frequent nightmares accelerate aging, increase risk of death
Nghtmares independently predict faster biological aging and earlier mortality — even after...
Cardiac organoids bring hope for treating heart disease
Australian scientists have developed lab-grown, three-dimensional heart tissues known as cardiac...
